Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Summit Therapeutics (SMMT) SMT C1100 Fully Enrolled in Trial Phase Ib; Needham & Company Reiterates Buy
June 12, 2015 7:30 AM EDTNeedham & Company reiterates a Buy rating and $22.00 price target on Summit Therapeutics plc (NASDAQ: SMMT) as SMT C1100 pharmacokinetics and muscle biomarkers trial is now fully enrolled and dosing patients. topline data is expected in 3Q15.
Analyst Chad Messer commented, "Summit... More
Summit Therapeutics (SMMT) Reports Q1 Loss of 6p/Share
June 11, 2015 7:07 AM EDTSummit Therapeutics (NASDAQ: SMMT) reported Q1 EPS of (GBP0.06), versus (GBP0.08) reported last year.
Mr Glyn Edwards, Chief Executive Officer of Summit commented: "During the first quarter, we substantially expanded our shareholder base with a successful NASDAQ listing, which has provided significant support for the on-going patient clinical trials of our lead product... More
